In April, we added 122 citations in DIDB, including 62 in vitro (with 19 articles published in May 2025) and 60 in vivo articles (with 35 articles published in May 2025).
3 NDA/BLAs approved in 2025, including atrasentan (VANRAFIA), fitusiran (QFITLIA), and nipocalimab (IMAAVY) were also curated in DIDB.
You can check the citations that are recently published and entered in DIDB and all the NDAs/BLAs in DIDB.
As always, feel free to contact us if you have any questions or comments.
In April, we added 128 citations in DIDB, including 67 in vitro (with 15 articles published in April 2025) and 61 in vivo articles (with 29 articles published in April 2025).
3 NDA approved in 2025, including gepotidacin (BLUJEPA), mirdametinib (GOMEKLI), and vimseltinib (ROMVIMZA) were also curated in DIDB.
You can check the citations that are recently published and entered in DIDB and all the NDAs/BLAs in DIDB.
As always, feel free to contact us if you have any questions or comments.
The DDI Marker Studies Knowledgebase has been updated in April 2025 and is available in the DIDB Resource Center.
In this update, we have continued identifying substrates, inhibitors, and inducers for CYP enzymes, UGTs, and various transporters. A total of 54 compounds were characterized, including substates of CYP2C9, CYP2C19, CYP3A, OAT1, OAT3, OCT2, MATE1, MATE2-K, and UGTs, inhibitors of CYP1A2, CYP2C8, CYP2C9, 2C19, CYP2D6, CYP3A, P-gp, BCRP, OAT1, OAT3, OATP1B1, OATP1B3, and UGTs, and inducers of CYP3A. Four compounds were identified as sensitive substrates of CYP3A based on dedicated DDI studies or PBPK modeling with itraconazole or ketoconazole. No strong inhibitors or inducers were identified in this update. Regarding UGTs, 10 drugs were characterized as UGT substrates, and 2 as inhibitors, supported by DDI or PGx data.
To view a comprehensive list of additions and modifications, including new compounds and updates to existing entries, you may use the “Recent Update” column (Column AE) on the spreadsheet and select “yes.”
In addition to substrates, inhibitors and inducers of CYPs and transporters, the Knowledgebase provides useful information on the compounds therapeutic class, clinical recommended dosage, pharmacokinetics (e.g., dose proportionality accumulation ratio, time to steady-state), QT prolongation, and NTI characteristics.
As always, feel free to contact us if you have any questions or comments.
In March, we added 106 citations in DIDB, including 50 in vitro (with 15 articles published in March 2025) and 56 in vivo articles (with 30 articles published in March 2025).
2 NDA/BLAs approved in 2025, including datopotamab deruxtecan (DATROWAY) and suzetrigine (JOURNEAVX), were also curated in DIDB.
You can check the citations that are recently published and entered in DIDB and all the NDAs/BLAs in DIDB.
As always, feel free to contact us if you have any questions or comments.
In February, we added 116 citations in DIDB, including 59 in vitro (with 21 articles published in February 2025) and 57 in vivo articles (with 44 articles published in February 2025).
4 NDA/BLAs approved in 2024, including concizumab (ALHEMO), ensifentrine (OHTUVAYRE), marstacimab (HYMPAVZI), vanzacaftor and tezacaftor and deutivacaftor (ALYFTREK), and 1 NDA approved in 2025, namely treosulfan (GRAFAPEX), were also curated in DIDB.
You can check the citations that are recently published and entered in DIDB and all the NDAs/BLAs in DIDB.
As always, feel free to contact us if you have any questions or comments.
Data curation for drug therapies approved by the FDA in 2024 has been completed. A total of 50 drugs was approved, comprising 34 NDAs and 16 BLAs. Nearly all of the NDAs have relevant in vitro and clinical findings related to drug interactions, food effect, organ impairment studies, and PGx data. PBPK modeling and simulations were deemed sufficient for 9 drugs to support DDI assessment and label recommendations. Drug monographs are also available, summarizing key DDI results, characteristics, QT information, and PK data.
The full list of NDA/BLAs entered into DIDB last year can be accessed at: https://didb.druginteractionsolutions.org/resources/all-ndas/
Do not hesitate to contact us with comments or suggestions.
In January, we added 112 citations in DIDB, including 63 in vitro (with 21 articles published in January 2025) and 49 in vivo articles (with 27 articles published in January 2025).
8 NDA/BLAs approved in 2024, including acoramidis (ATTRUBY), cosibelimab (UNLOXCYT), crinecerfont (CRENESSITY), ensartinib (ENSACOVE), iomeprol (IOMERVU), landiolol (RAPIBLYK), olezarsen (TRYNGOLZA), and zenocutuzuma (BIZENGRI) were also curated in DIDB.
You can check the citations that are recently published and entered in DIDB and all the NDAs/BLAs in DIDB.
As always, feel free to contact us if you have any questions or comments.
The DDI Marker Studies Knowledgebase has been updated in January 2025 and is available in the DIDB Resource Center.
In this update, we have continued identifying substrates, inhibitors, and inducers for CYP enzymes and various transporters. A total of 20 compounds were characterized, including substates of CYP2C9, CYP3A, BCRP, OAT1, and OAT3, inhibitors of CYP2C19, CYP2D6, P-gp, BCRP, and OCT2, and inducers of CYP2C19 and P-gp. No strong perpetrators or sensitive substrates were identified.
To view a comprehensive list of additions and modifications, including new compounds and updates to existing entries, you may use the “Recent Update” column (Column AE) on the spreadsheet and select “yes.”
In addition to substrates, inhibitors and inducers of CYPs and transporters, the Knowledgebase provides useful information on the compounds therapeutic class, clinical recommended dosage, pharmacokinetics (e.g., dose proportionality accumulation ratio, time to steady-state), QT prolongation, and NTI characteristics.
As always, feel free to contact us if you have any questions or comments.
In December, we added 106 citations in DIDB, including 56 in vitro (with 22 articles published in December 2024) and 50 in vivo articles (with 41 articles published in December 2024).
3 NDA/BLAs approved in 2024, including revumenib (REVUFORJ), sulopenem and probenecid (ORLYNVAH), and zanidatama (ZIIHERA) were also curated in DIDB.
You can check the citations that are recently published and entered in DIDB and all the NDAs/BLAs in DIDB.
As always, feel free to contact us if you have any questions or comments.
Presented at the ISPOR Europe, November 2024
Nadia Quignot, Nina Shigesi, Kazue Kikuchi, Sophie Argon, and Isabelle Ragueneau-Majlessi
Evaluating DDIs in a real-world setting is key to accurately assess the clinical and economic outcomes of drugs. Real-World Data (RWD) can help in identifying potential DDIs, assessing their clinical significance, guiding dose adjustments to manage potential DDIs, and supporting overall benefit-risk assessment of drugs or drug combinations. This literature review aimed to characterize current applications of RWD in evaluating and mitigating DDI risks, while identifying gaps to be addressed.